UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________

 

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 31, 2013

 

Array BioPharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware 84-1460811
(State or Other Jurisdiction of
 Incorporation or Organization)		 (I.R.S. Employer Identification No.)
   
3200 Walnut Street, Boulder, CO 80301
(Address of Principal Executive Offices) (Zip Code)
   
(303) 381-6600  
(Registrant’s Telephone Number, Including Area Code)  
     

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

On October 31, 2013, Array BioPharma Inc. issued a press release reporting results for the first quarter of fiscal year ending June 30, 2014, the full text of which is attached hereto as Exhibit 99.1.

 

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

99.1Press release dated October 31, 2013 entitled “Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2014 and Announces ARRY-520 Development Strategy.”

 

 

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  ARRAY BIOPHARMA INC.
   
Date: October 31, 2013 By:  /s/ R. Michael Carruthers
  R. Michael Carruthers
Chief Financial Officer

 

 
 

  

EXHIBIT INDEX

Exhibit No.

 

99.1Press release dated October 31, 2013 entitled “Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2014 and Announces ARRY-520 Development Strategy.”